FIELD: pharmacology.
SUBSTANCE: group of inventions concerns pharmaceutical compositions for treatment of diabetes or obesity, containing the first type of granules and the second type of granules, where the specified first type of granules contains the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and does not contain GLP-1 peptide, and where the specified second type of granules contains GLP-1 peptide and does not contain the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and also refers to methods for composition production and application in medicine.
EFFECT: improving the bioavailability of the GLP-1 peptide.
33 cl, 10 ex, 12 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID COMPOSITIONS CONTAINING AGONIST TO GLP AND SALT OF N-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | 2011 |
|
RU2600440C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT AND LUBRICANT | 2019 |
|
RU2807183C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT | 2019 |
|
RU2804318C2 |
| ORAL DOSING OF GLUCAGON-LIKE PEPTIDE-1 COMPOUNDS | 2014 |
|
RU2671406C2 |
| DOUBLE-ACYLATED GLP-1 DERIVATIVES | 2010 |
|
RU2559540C2 |
| SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
| DIPEPTIDE, CONTAINING NONPROTEINOGENIC AMINO ACID | 2012 |
|
RU2643515C2 |
| NOVEL GLUCAGON ANALOGUES | 2012 |
|
RU2610175C2 |
| GLUCAGON-LIKE PEPTIDE-1 (GLP-1) DERIVATIVES | 2004 |
|
RU2401276C2 |
| ACYLATED GLP-1 COMPOUNDS | 2006 |
|
RU2434019C2 |
